<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01734746</url>
  </required_header>
  <id_info>
    <org_study_id>NL40323.068.12</org_study_id>
    <nct_id>NCT01734746</nct_id>
  </id_info>
  <brief_title>Sentinel Node Detection in Clinical Early Stage Ovarian Cancer</brief_title>
  <acronym>SONAR</acronym>
  <official_title>Sentinel Node Detection in Clinical Early Stage Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As most cancers, ovarian cancer also spreads to regional lymph nodes. The concept of sentinel&#xD;
      lymph node surgery is to see whether the cancer has spread to the very first lymph node or&#xD;
      sentinel node (SN). If the sentinel node does not contain cancer, there is a high likelihood&#xD;
      that the cancer has not spread to other lymph nodes. This means that, at least theoretically,&#xD;
      a radical lymphadenectomy could be omitted and thus the associated morbidity. The sentinel&#xD;
      node technique has been proven to be effective in different cancers such as breast cancer and&#xD;
      malignant melanoma. In gynaecological tumors it has been shown to be effective in vulvar&#xD;
      cancer. Currently sentinel node studies are done for cervix and uterine cancer.&#xD;
&#xD;
      The present study determines whether or not a sentinel node procedure in patients with&#xD;
      ovarian cancer is feasible when the tracers are injected in the ovarian ligaments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the International Federation of Gynecology and Obstetrics (FIGO), Epithelial&#xD;
      Ovarian Cancer (EOC) with lymph node metastases is classified as FIGO stage IIIC disease,&#xD;
      even in the absence of peritoneal metastases. In contrast to patients with FIGO stage I&#xD;
      ovarian cancer after a comprehensive staging procedure, patients with a FIGO stage III&#xD;
      ovarian cancer obtain adjuvant chemotherapy. Therefore, the recognition of lymph node&#xD;
      metastases is of utmost importance. In general, the incidence of lymph node metastases in&#xD;
      clinical early stage EOC is approximately 14%, and depends on subtype histology (i.e. serous&#xD;
      23%, mucinous 3%) and differentiation grade (4% and 20% in grade 1 and 3 tumors&#xD;
      respectively).&#xD;
&#xD;
      Surgical staging of EOC and the extent of lymph node dissection differs greatly from centre&#xD;
      to centre. In case of a clinical early stage ovarian cancer, the Dutch guideline recommends a&#xD;
      staging laparotomy with adequate lymph node sampling, with an absolute minimum of ten lymph&#xD;
      nodes removed. In the same guideline, a footnote is made stating that a larger number of&#xD;
      removed lymph nodes will increase the chance of finding metastases. These lymph nodes also&#xD;
      need to be sampled from different anatomical regions, of which the most important are the&#xD;
      para-aortic and paracaval region between the renal vein and inferior mesenteric artery, the&#xD;
      common, internal and external iliac vessels and the obturator fossa.&#xD;
&#xD;
      A systematic lymphadenectomy can be seen as the golden standard. However, such a radical&#xD;
      procedure gives more late morbidity than lymph node sampling. These include the formation of&#xD;
      lymphocyst (up to 13.5%), nerve and vessel injury (up to 4%), and increased blood loss and&#xD;
      operating time [26, 27]. Studies done for sentinel node in ovarian cancer are very limited&#xD;
      and performed in women with uterine cancer by injecting the tracers in the ovary. In case of&#xD;
      ovarian cancer such a procedure gives a possible risk of tumour dissemination. In this&#xD;
      feasibility study the tracers are injected in the ligaments of the ovary, not in the cortex&#xD;
      itself.&#xD;
&#xD;
      Patients with (suspicion of) ovarian cancer as well as patients with a high-grade uterine&#xD;
      carcinoma will be included. The latter group of patients can also be included because these&#xD;
      patients undergo the same surgical procedure; Total Abdominal Hysterectomy (TAH) with&#xD;
      Bilateral Salpingo-Oophorectomy (BSO) and a pelvic and para-aortic lymphadenectomy or lymph&#xD;
      node sampling.&#xD;
&#xD;
      Both blue dye and the radioactive isotope will be injected in the ligamentum ovarii proprium&#xD;
      (median side) and the ligamentum infundibulo-pelvicum (lateral side), close to the ovary and&#xD;
      just below the peritoneum.&#xD;
&#xD;
      In case of an ovarian tumor: after 15 minutes time-interval the ovarian mass will be removed&#xD;
      and presented to the pathologist for a frozen section. If the result is benign, no further&#xD;
      actions will be performed in these patients. If the result is malignant, the sentinel node(s)&#xD;
      will be identified either by the radioactive tracer and / or visually (blue dye) after&#xD;
      opening the retroperitoneal space. After removal of the sentinel node(s) a complete standard&#xD;
      staging procedure will be performed including a comprehensive sampling of other lymph nodes&#xD;
      at the different locations.&#xD;
&#xD;
      In case of endometrial cancer: after 15 minutes time-interval the surgical staging procedure&#xD;
      starts with a TAH and BSO. After approximately 45 minutes the sentinel node(s) will be&#xD;
      identified either by the radioactive tracer and / or visually (blue dye) after opening the&#xD;
      retroperitoneal space. This 45 minutes time-interval is chosen to mimic the time interval&#xD;
      when a frozen section is performed in case of an ovarian tumor. After removal of the sentinel&#xD;
      node(s) a complete standard staging procedure will be performed including a comprehensive at&#xD;
      random sampling of other lymph nodes at the different locations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients (%) in Which Sentinel Node(s) Are Detected After Injection of Blue Dye and Tracer in the Ovarian Ligaments.</measure>
    <time_frame>During surgery.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anatomical Location(s) of the Sentinel Nodes.</measure>
    <time_frame>During surgery.</time_frame>
    <description>The number of patients with only paraaortic/paracaval, only pelvic, and both paraaortic/paracaval and pelvic sentinel node locations.patients.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Patients With False Negative Sentinel Nodes.</measure>
    <time_frame>During surgery.</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Sentinel Node</condition>
  <arm_group>
    <arm_group_label>Tracerinjection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention concerns tracerinjection (both blue dye and the radioactive isotope beingtechnetium-99-m-labeled albumin nanocolloid) in the ligamentum ovarii proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), close to the ovary and just below the peritoneum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tracerinjection</intervention_name>
    <description>The intervention concerns the tracerinjection for detection of the sentinel node.</description>
    <arm_group_label>Tracerinjection</arm_group_label>
    <other_name>99mTc-nanocolloid or Nanocoll</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a high suspicion of a malignant ovarian tumour planned for exploratory&#xD;
             laparotomy.&#xD;
&#xD;
          -  Patients with high-risk endometrial cancer in whom a staging laparotomy is planned.&#xD;
&#xD;
          -  Age between 18 and 85 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous surgery of both ovaries.&#xD;
&#xD;
          -  Previous vascular surgery of the aorta, caval vein, and/or iliac vessels.&#xD;
&#xD;
          -  Previous lymphadenectomy of lymph node sampling in the iliac or para-aortal region.&#xD;
&#xD;
          -  History of a malignant lymphoma.&#xD;
&#xD;
          -  History of a malignant tumour in the abdominal cavity.&#xD;
&#xD;
          -  Previous allergic reaction to blue dye.&#xD;
&#xD;
          -  Pregnant or lactating patients.&#xD;
&#xD;
          -  An allergy for human albumin.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy Kruitwagen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Maastricht UMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MaastrichtUMC</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>October 31, 2012</study_first_submitted>
  <study_first_submitted_qc>November 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2012</study_first_posted>
  <results_first_submitted>July 29, 2015</results_first_submitted>
  <results_first_submitted_qc>April 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2018</results_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>sentinel node</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 28, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT01734746/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sentinel Node Procedure</title>
          <description>Injection of both blue dye and the radioactive isotope (technetium-99-m-labeled albumin nanocolloid) in the ligamentum ovarii proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), close to the ovary and just below the peritoneum.&#xD;
blue dye and radioactive tracer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sentinel Node Procedure</title>
          <description>Injection of both blue dye and the radioactive isotope (technetium-99-m-labeled albumin nanocolloid) in the ligamentum ovarii proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), close to the ovary and just below the peritoneum.&#xD;
blue dye and radioactive tracer</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age (categorical) of participants at the time of surgery.;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Ages (continuous) of participants at the time of surgery.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" lower_limit="22" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients (%) in Which Sentinel Node(s) Are Detected After Injection of Blue Dye and Tracer in the Ovarian Ligaments.</title>
        <time_frame>During surgery.</time_frame>
        <population>see Kleppe et al., J Nucl Med 2014; 55:1799-1804</population>
        <group_list>
          <group group_id="O1">
            <title>Sentinel Node Procedure</title>
            <description>Injection of both blue dye and the radioactive isotope (technetium-99-m-labeled albumin nanocolloid) in the ligamentum ovarii proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), close to the ovary and just below the peritoneum.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients (%) in Which Sentinel Node(s) Are Detected After Injection of Blue Dye and Tracer in the Ovarian Ligaments.</title>
          <population>see Kleppe et al., J Nucl Med 2014; 55:1799-1804</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anatomical Location(s) of the Sentinel Nodes.</title>
        <description>The number of patients with only paraaortic/paracaval, only pelvic, and both paraaortic/paracaval and pelvic sentinel node locations.patients.</description>
        <time_frame>During surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sentinel Node Procedure</title>
            <description>Injection of both blue dye and the radioactive isotope (technetium-99-m-labeled albumin nanocolloid) in the ligamentum ovarii proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), close to the ovary and just below the peritoneum.</description>
          </group>
        </group_list>
        <measure>
          <title>Anatomical Location(s) of the Sentinel Nodes.</title>
          <description>The number of patients with only paraaortic/paracaval, only pelvic, and both paraaortic/paracaval and pelvic sentinel node locations.patients.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SN only paraaortic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SN only pelvic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SN both paraortic and pelvic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With False Negative Sentinel Nodes.</title>
        <time_frame>During surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sentinel Node Procedure</title>
            <description>Injection of both blue dye and the radioactive isotope (technetium-99-m-labeled albumin nanocolloid) in the ligamentum ovarii proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), close to the ovary and just below the peritoneum.&#xD;
blue dye and radioactive tracer</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With False Negative Sentinel Nodes.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sentinel Node Procedure</title>
          <description>Injection of both blue dye and the radioactive isotope (technetium-99-m-labeled albumin nanocolloid) in the ligamentum ovarii proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), close to the ovary and just below the peritoneum.&#xD;
blue dye and radioactive tracer</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>R.F.P.M. Kruitwagen</name_or_title>
      <organization>MaastrichtUMC</organization>
      <phone>+31433874767</phone>
      <email>r.kruitwagen@mumc.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

